These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 19049379

  • 21. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [Abstract] [Full Text] [Related]

  • 22. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.
    Rassam AG, Zeise TM, Burge MR, Schade DS.
    Diabetes Care; 1999 Jan; 22(1):133-6. PubMed ID: 10333914
    [Abstract] [Full Text] [Related]

  • 23. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM, Noble S, Goa KL.
    Drugs; 2002 Jan; 62(13):1945-81. PubMed ID: 12215068
    [Abstract] [Full Text] [Related]

  • 24. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A.
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [Abstract] [Full Text] [Related]

  • 25. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D, Rizzi A, Scavone G, Tanese L, Zaccardi F, Manto A, Ghirlanda G.
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [Abstract] [Full Text] [Related]

  • 26. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
    Heise T, Zijlstra E, Nosek L, Rikte T, Haahr H.
    Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
    [Abstract] [Full Text] [Related]

  • 27. Impact of insulins glulisine and aspart on postprandial glycemia after a high-glycemic index meal in children with type 1 diabetes.
    Dzygalo K, Szypowska A.
    Eur J Endocrinol; 2014 Apr; 170(4):539-45. PubMed ID: 24412929
    [Abstract] [Full Text] [Related]

  • 28. Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear.
    Rini CJ, McVey E, Sutter D, Keith S, Kurth HJ, Nosek L, Kapitza C, Rebrin K, Hirsch L, Pettis RJ.
    Drug Deliv Transl Res; 2015 Aug; 5(4):332-45. PubMed ID: 26037035
    [Abstract] [Full Text] [Related]

  • 29. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
    DeFelippis MR, Bell MA, Heyob JA, Storms SM.
    Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
    [Abstract] [Full Text] [Related]

  • 30. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I, Ortego J, Valencia I, García-Palacios MV, Aguilar-Diosdado M.
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [Abstract] [Full Text] [Related]

  • 31. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.
    Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G.
    Diabetes Care; 2003 Jul; 26(7):2027-31. PubMed ID: 12832307
    [Abstract] [Full Text] [Related]

  • 32. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.
    Raskin P, Holcombe JH, Tamborlane WV, Malone JI, Strowig S, Ahern JA, Lavent F.
    J Diabetes Complications; 2001 Jul; 15(6):295-300. PubMed ID: 11711322
    [Abstract] [Full Text] [Related]

  • 33. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.
    Home PD, Lindholm A, Hylleberg B, Round P.
    Diabetes Care; 1998 Nov; 21(11):1904-9. PubMed ID: 9802741
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.
    Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB, CONTROL Study Group.
    Diabetes Technol Ther; 2008 Feb; 10(1):1-10. PubMed ID: 18275357
    [Abstract] [Full Text] [Related]

  • 35. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE.
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [Abstract] [Full Text] [Related]

  • 36. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
    Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode B.
    Diabetes Obes Metab; 2019 Apr; 21(4):1066-1070. PubMed ID: 30565407
    [Abstract] [Full Text] [Related]

  • 37. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.
    Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.
    Clin Ther; 2000 Feb; 22(2):222-30. PubMed ID: 10743981
    [Abstract] [Full Text] [Related]

  • 38. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII).
    Shashaj B, Busetto E, Sulli N.
    Diabet Med; 2008 Sep; 25(9):1036-42. PubMed ID: 18937673
    [Abstract] [Full Text] [Related]

  • 39. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.
    Rom J Intern Med; 2003 Sep; 41(2):153-62. PubMed ID: 15526500
    [Abstract] [Full Text] [Related]

  • 40. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR, Waters DL, Holcombe JH, Schade DS.
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.